- In April 2023, Thermo Fisher Scientific Inc. expanded its portfolio of chemically competent cells with the launch of One Shot MAX Efficiency DH5α-T1R Competent Cells, offering ultra-high transformation efficiency for cloning difficult DNA sequences. This development addresses researchers' growing needs for consistent and high-yield cloning results, reflecting Thermo Fisher's ongoing commitment to advancing molecular biology tools with user-friendly, high-performance solutions
- In March 2023, Merck KGaA (MilliporeSigma) introduced a new range of electrocompetent cells under its Novagen brand, engineered for high-throughput applications in protein expression and synthetic biology. These cells are optimized for large plasmid uptake and difficult-to-clone genes, providing a valuable tool for biotech and academic researchers. The launch reinforces Merck’s strategic focus on facilitating precision and scalability in genetic engineering
- In February 2023, Takara Bio Inc. announced the release of HST08 Premium Competent Cells, specifically designed for high-efficiency cloning and library construction. This product was developed in response to increasing demand from pharmaceutical and biotech companies for reliable transformation systems in gene therapy and vaccine research. Takara’s expansion in competent cells strengthens its product line aimed at supporting advanced genomic applications
- In February 2023, Lucigen (a division of LGC Biosearch Technologies) launched its E. cloni® Supreme Electrocompetent Cells, offering high transformation efficiency for next-generation sequencing (NGS) and synthetic biology applications. The cells were developed to enhance the construction of large libraries and improve representation in complex workflows, illustrating Lucigen’s focus on supporting advanced genomic discovery tools
- In January 2023, Agilent Technologies Inc. expanded its competent cell offerings with new SureVector Compatible Cells tailored for seamless integration into Agilent’s cloning and assembly workflows. This update enables faster project timelines and improved transformation success, particularly for synthetic biology applications. Agilent’s move emphasizes its commitment to workflow integration and end-to-end molecular biology solutions
